ACRO BIOMEDICAL CO., LTD. (ACBM)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 6, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, ACRO BIOMEDICAL CO., LTD. reported revenue of $0, net income of -$21,356, and total assets of $3,648. Every figure below is taken directly from ACRO BIOMEDICAL CO., LTD.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2017–FY2025 · as reported
- FY2017 revenue
- $510,000
- FY2025 revenue
- $0
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $0 | -$101,146 |
| FY2024 | $0 | -$42,297 |
| FY2023 | $0 | -$8.8M |
| FY2022 | $658,500 | -$15.9M |
| FY2021 | $1.2M | -$7.7M |
| FY2020 | $687,964 | -$117,453 |
| FY2019 | $193,536 | -$371,604 |
| FY2018 | $8.0M | $419,660 |
| FY2017 | $510,000 | -$2,248 |
| FY2016 | — | -$43,428 |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Sep 2, 2026 | on EDGAR ↗ |
| 10-Q | Aug 14, 2026 | on EDGAR ↗ |
| 10-Q | May 5, 2026 | on EDGAR ↗ |
| 10-K | Feb 11, 2026 | on EDGAR ↗ |
| 8-K | Jan 8, 2026 | on EDGAR ↗ |
| 10-Q | Nov 10, 2025 | on EDGAR ↗ |
| 8-K | Aug 14, 2025 | on EDGAR ↗ |
| 10-Q | Aug 5, 2025 | on EDGAR ↗ |
| 10-K | Jul 24, 2025 | on EDGAR ↗ |
| 10-Q | Jul 24, 2025 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $0.00 | Earnings | source ↗ |
| EPS (basic) | — | — | source ↗ |
| Shares Outstanding | 60.0M | Entity | source ↗ |
| Cash from Operations | -$10,504 | Net | source ↗ |
| Cash from Financing | $10,279 | Net | source ↗ |
| Cash from Investing | — | — | source ↗ |
Restatement history
Point-in-time1 of 216 annual fact-keys were materially restated between filings: what ACRO BIOMEDICAL CO., LTD. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches ACBM’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/ACBM
MCP tool:
get_sec_fundamentals ticker=ACBM - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/ACBM/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=ACBM as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/ACBM/history
MCP tool:
get_fundamentals_history ticker=ACBM - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/ACBM
MCP tool:
get_financial_health ticker=ACBM
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.